Drug Trial Radar · NCT02552238
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
Last checked: Nov 20, 2026Latest source record: Jul 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Oct 12, 2015
Primary completion
Jun 22, 2017
Study completion Feb 25, 2018
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
Conditions
- Coronary Artery Disease
Interventions
LumasonDrug
Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and Specificity of Lumason Enhanced Dobutamine Stress Echo (DSE) for Detection or Exclusion of Coronary Artery Disease (CAD)Time frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed
- Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic ImagesTime frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Coastal Multi-Specialty Research, Coastal Heart Medical Group
Santa Ana, California
Alfieri Cardiology
Wilmington, Delaware
Homestead Cardiac and Vein Center
Homestead, Florida
Ochsner Clinic Foundation
New Orleans, Louisiana
St. Louis University Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Duke University Medical Center Cardiac Diagnostic Unit
Durham, North Carolina
University of Texas Medical Branch at Galveston
Galveston, Texas
Cliniques Universitaires Saint-Luc Unité de Pathologie Cardio-Vasculaire / Cardiologie
Brussels, Belgium
Antwerp University Hospital
Edegem, Belgium
St. Michael's Hospital
Toronto, Ontario, Canada
Hammersmith Hospital
London, United Kingdom
Northwick Park Hospital
Harrow, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.